GenomeDx Biosciences Closes Series A Financing Round

GenomeDx Biosciences Inc., a Vancouver, BC, Canada-based molecular diagnostic company, has closed a Series A financing round of undisclosed amount.

The round was co-led by Baird Venture Partners and aeris CAPITAL, with participation from CD Ventures and individual investors.

Led by CEO Doug Dolginow, M.D., GenomeDx develops molecular diagnostic tests and clinical support tools for cancer medicine.

In conjunction with the funding, Mike Liang, Ph.D., BVP Partner, and George Rehm, managing partner at aeris CAPITAL, will join the company’s Board of Directors.



Join the discussion